Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232086 | 0.80 | MMP9 (0.47) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL354251 | 0.80 | MMP9 (0.47) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL354252 | 0.80 | MMP9 (0.47) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL12340944 | 0.79 | UGT2B7 (0.49) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL24818356 | 0.78 | UGT2B7 (0.47) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL7502070 | 0.78 | UGT2B7 (0.50) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL8019892 | 0.78 | RIPK1 (0.44) | KMT2AAOC3 | |
| SCHEMBL20193367 | 0.77 | UGT2B7 (0.58) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL10583623 | 0.76 | UGT2B7 (0.49) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL10580009 | 0.76 | UGT2B7 (0.49) | UGT2B7MEN1KMT2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | UGT2B7 210/4885MEN1 3289/4885KMT2A 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.